对CAR-T细胞扩张和持续性缺陷的机制和对策
Yu-Tong Bao1, Meng Lv1, Xiao-Jun Huang2
1Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Beijing, China.
化学抗原受体 (CAR) T细胞疗法对血液癌症有希望,但面临复发和持续性的挑战. 本综述探讨了限制CAR-T细胞疗效的因素以及改善其扩张和持久性的策略,以获得更好的患者结果.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞疗法细胞疗法
背景情况:
- 化学抗原受体 (CAR) T细胞疗法是B细胞恶性瘤的革命性治疗方法.
- 在某些白血病 (如CLL和AML) 中,有限的疗效和高的复发率限制了其临床使用.
- 治疗成功的关键是CAR-T细胞的扩张,透和持续性.
研究的目的:
- 审查CAR-T细胞扩张和在血液恶性瘤和固体瘤中持久性的特征.
- 阐明CAR-T细胞扩张和持久性的缺陷背后的机制.
- 总结了提高CAR-T细胞疗效的策略.
主要方法:
- 关于CAR-T细胞治疗研究的文献综述.
- 对影响CAR-T细胞扩张和持久性的因素的分析.
- 关于CAR-T细胞介导免疫反应的当前知识的综合.
主要成果:
- 有限的CAR-T细胞扩张和持久性显著导致治疗失败和复发.
- 缺陷的机制涉及内在的CAR-T细胞因子和瘤免疫微环境.
- 有各种方法可以改善CAR-T细胞质量并克服免疫抑制.
结论:
- 增强CAR-T细胞扩张和持久性对于克服治疗局限性至关重要.
- 解决内在的CAR-T细胞缺陷和免疫抑制环境可以改善治疗结果.
- 对优化CAR-T细胞治疗的进一步研究是有必要的,以获得更广泛的临床应用.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
相关概念视频
Cell-mediated Immune Responses
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Tumor Immunotherapy
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
